Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
NCT ID: NCT00406081
Last Updated: 2017-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
69 participants
OBSERVATIONAL
2005-12-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
NCT00723489
Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus
NCT00407069
Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis
NCT00801957
Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis
NCT00379678
Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis
NCT00310492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will consist of one study visit occurring about 2 to 16 weeks after the child received the chicken pox vaccination. During this visit, physical and skin exams will occur. Personal and family medical histories and blood collection will also occur. The chicken pox vaccine will not be given as a part of this study. Subjects will receive the results of radioallergosorbent (RAST) testing that will tell if they are allergic to some common items (e.g., mold, grass).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with AD
Children with AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit (including a group of AD subjects with eczema herpeticum)
No interventions assigned to this group
Nonatopic controls
Children without AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female of any race or ethnicity
* 12 to 36 months of age, inclusive
* Healthy subjects with no systemic disorders and subjects with moderate to severe AD including a group of subjects with ADEH+
* Previously vaccinated for varicella by a physician 3 weeks prior to the Study Visit (subjects receiving the vaccine 2-16 weeks prior will also be accepted)
Exclusion Criteria
* Oral, intravenous, or intramuscular corticosteroids within 30 days prior to chicken pox immunization
* Asthmatics receiving more than 500 micrograms per day of inhaled budesonide or more than 220 micrograms per day of inhaled fluticasone
* Antiherpes antiviral agents within 7 days prior to immunization
* Suspected immune deficiency or family history of primary immunodeficiency
* History of or active cancer
* Active untreated tuberculosis (TB)
* Respiratory illness at the time of chicken pox vaccination
* Receipt of blood products or chicken pox zoster immune globulin within the last 5 months prior to study entry
12 Months
36 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lynda Schneider, MD
Role: STUDY_CHAIR
Boston Children's Hospital
Donald Y. Leung, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
National Jewish Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Jewish Health
Denver, Colorado, United States
Children's Hospital Boston
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schneider L, Weinberg A, Boguniewicz M, Taylor P, Oettgen H, Heughan L, Zaccaro D, Armstrong B, Holliday A, Leung DY. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. J Allergy Clin Immunol. 2010 Dec;126(6):1306-7.e2. doi: 10.1016/j.jaci.2010.08.010.
Related Links
Access external resources that provide additional context or updates about the study.
National Institute of Allergy and Infectious Diseases (NIAID)
Division of Allergy, Immunology, and Transplantation (DAIT)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Contract No. HHSN266200400029C
Identifier Type: -
Identifier Source: secondary_id
DAIT ADVN VAR 05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.